| 1 |
卢佳配,温树鹏,王福旭.恶性血液病异基因造血干细胞移植后复发单中心临床分析[J].中国实验血液学杂志, 2022, 30(4):1238-1243.
|
| 2 |
Valkova V, Jircikova J, Trnkova M, et al. The quality of life following allogeneic hematopoietic stem cell transplantation-a multicenter retrospective study[J]. Neopl-asma, 2016, 63(5):743-751.
|
| 3 |
Fein JA, Shimoni A, Labopin M, et al. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation[J]. Leukemia, 2018, 32(8): 1787-1794.
|
| 4 |
Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation[J]. Lancet Haematol, 2020, 7(2):e157-e167.
|
| 5 |
Sakata-Yanagimoto M, Fukumoto K, Karube K, et al. Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category[J]. Clin Exp Hematop, 2021, 61(2):61-70.
|
| 6 |
Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma[J].Clin Epigenetics, 2020, 12(1):169.
|
| 7 |
Cao C, Feng J, Gu H, et al. Distribution of lymphoid neoplasms in Northwest China: Analysis of 3244 cases according to WHO classification in a single institution[J]. Ann Diagn Pathol, 2018, 34:60-65.
|
| 8 |
Armitage JO. The aggressive peripheral T-cell lymphomas: 2017[J]. Am J Hematol, 2017, 92(7):706-715.
|
| 9 |
|
| 10 |
Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation:an update[J]. Blood Cancer J, 2011, 1(4):e16.
|
| 11 |
Danylesko I, Shimoni A. Second malignancies after hematopoietic stem cell transplantation[J]. Curr Treat Options Oncol, 2018, 19(2):9.
|
| 12 |
Gifford G, Sim J, Horne A, et al. Health status, late effects and long-term survivorship of allogeneic bone marrow transplantation:a retrospective study[J]. Intern Med Journal, 2014, 44(2):139-147.
|
| 13 |
Shibusawa M, Kidoguchi K, Tanimoto T. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders[J]. In: Gallamini A, Juweid M, editors. Lymphoma [Internet]. Brisbane(AU): Exon Publications, 2021 Dec28, Chapter 4. PMID:35226434. DOI: 10.36255/exon-publications.lymphoma.2021.oil-lpd.
|
| 14 |
汤佳音.移植后淋巴增殖异常[J].肝胆胰外科杂志, 2018, 20(1):70-73.
|
| 15 |
刘霆.外周T细胞淋巴瘤的诊断和治疗进展[J].中华血液学杂志, 2014, 35(4):361.
|
| 16 |
Lau E, Moyers JT, Wang BC, et al. Analysis of post-transplant lymphoproli-ferative disorder (PTLD) outcomes with epstein-barr virus (EBV) assessments-a single tertiary referral center experience and review of literature[J]. Cancers (Basel), 2021, 13(4):899.
|
| 17 |
Kieser A, Sterz KR. The latent membrane protein 1 (LMP1)[J]. Curr Top Microbiol Immunol, 2015, 391:119-149.
|
| 18 |
Taylor AL, Marcus R. Post-transplant lymphoproliferative disorders (PTLD)after solid organ transplantation[J]. Crit Rev Oncol Hematol, 2005, 56:156-167.
|
| 19 |
Polyatskin IL, Artemyeva AS, Krivolapov YA. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition): lymphoid tumors [J]. Arkh Patol, 2019, 81(3):59-65.
|
| 20 |
Szlauer-Stefańska A, Kamińska-Winciorek G, et al. Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures[J]. Adv Clin Exp Med, 2020, 29(10):1221-1230.
|
| 21 |
展新荣,梁波,王羽,等.急性粒细胞白血病继发第二肿瘤的临床观察[J].中国实用医学, 2010, 5(31):110-111.
|